Jaguar Health stock swings as Future Pak licensing deal dangles $38 million — here’s what traders see
Jaguar Health shares fell about 9% Monday after announcing a U.S. licensing deal with Future Pak for exclusive rights to Mytesi and Canalevia-CA1, potentially worth up to $38 million. The stock traded between $0.94 and $1.45 on heavy volume. Jaguar will receive $18 million upfront and may get up to $20 million more in milestone payments, while shifting its U.S. commercial focus to Future Pak.
